CoVID-19 Ocugen Vaccine Development Partner Bharat Biotech shares Phase 3 Interim results of COVAXIN demonstrate 81% Nasdaq efficacy: OCGN
European Commission awards Ocugen for orphan drugs for drugs for gene therapy, candidate for OCU400, for the treatment of both retinitis pigmentosa and congenital Leber amebrosis
